PRESS RELEASE
13 March 2024

Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX

CL
Cooley LLP

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Reston – March 6, 2024 – Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies
United States

Reston – March 6, 2024 – Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX (NYSE: PHGE), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Lawyers Christian Plaza, Matthew Silverman, Brian Leaf, Matthew Schwee, Joyce Li and Rasha Printz led the Cooley team advising APT.

Immediately after the effective date of the merger, BiomX will own approximately 55%, and the former stockholders of APT will own approximately 45%, of the consolidated entity of BiomX and APT. The merger is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement.

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More